Cytovale Names Dave Vort Chief Commercial Officer

Proven Medical Device Executive Joins Cytovale to Drive Commercial Growth of the Company's IntelliSep^® Rapid Sepsis Detection Technology

SAN FRANCISCO, Feb. 4, 2025 /PRNewswire/ -- Cytovale^®, a commercial-stage medical diagnostics company, today announced the appointment of Dave Vort as its new chief commercial officer. With more than 25 years of experience in the medical device sector, he will lead commercialization and market expansion as the company addresses dramatically growing demand for its artificial intelligence (AI)-enabled U.S. Food and Drug Administration (FDA)-cleared rapid sepsis detection solution, IntelliSep^®.

"With our latest $100 million funding and strong interest in IntelliSep, Cytovale is solidifying its position as a leader in providing hospitals with essential tools to swiftly address and treat the life-threatening condition of sepsis," said Ajay Shah, Cytovale co-founder and CEO. "Expanding our team with top-tier expertise is crucial as we continue to grow our presence in hospitals and emergency departments nationwide. Dave's proven track record in commercializing high-growth medical technologies and navigating complex markets will be pivotal as we lay a robust foundation for Cytovale's next phase."

Vort joins Cytovale from Magnus Medical, where he served as president of the medical device company that developed novel, rapid-acting brain stimulation technology for treating patients with major depressive disorders. Prior to this, Vort was CCO at iRhythm Technologies Inc., where he built a commercial organization that grew revenue from $21.7 million to $492 million. iRhythm raised $107 million in a 2016 IPO.

"I am thrilled to join the extraordinary team at Cytovale, where innovation and purpose intersect to tackle one of the most urgent challenges in healthcare today. Every year, this preventable condition claims countless lives. It contributes to more than one-third of all in-hospital deaths and burdens our healthcare system with billions in unnecessary costs," Vort said. "At Cytovale, I see the opportunity not only to bring revolutionary products and services to patients worldwide, but to drive meaningful change by reducing – and ultimately eliminating – this devastating problem. I am deeply motivated by the chance to help improve outcomes for patients and empower healthcare providers with the tools they need to save lives. Together, we will transform the way hospitals address sepsis and make a lasting impact on global healthcare."

Earlier this month, Cytovale shared details about its growth over the first full year of commercialization and offered insights into increasing demand for its AI-enabled IntelliSep, which uses a standard blood draw to risk-stratify patients based on their probability of having sepsis within about eight minutes.

About Cytovale^®

Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale's U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, IntelliSep^®, leverages machine learning and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis. IntelliSep measures the dysregulated immune system response to infection that would indicate sepsis and generates results in about eight minutes using a standard blood draw. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital and Global Health Investment Corporation (GHIC). For more information, visit www.cytovale.com and follow Cytovale on LinkedIn and X.

SOURCE Cytovale